MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgae479

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2025

Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals.

Aleksic Sandra, Lontchi-Yimagou Eric, Mitchell William, Boyle Caroline, Matias Priyanka, Manavalan Anjali, Goyal Akankasha, Carey Michelle, Gabriely Ilan, Hawkins Meredith

СтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

CONTEXT: Hypoglycemia-associated autonomic failure (HAAF), defined as blunting of counterregulatory hormone and symptom responses to recurrent hypoglycemia, remains a therapeutic challenge in diabetes treatment. The opioid system may play a role in HAAF pathogenesis since activation of opioid receptors induces HAAF. Blockade of opioid receptors with intravenous naloxone ameliorates HAAF experimentally yet is not feasible therapeutically.

OBJECTIVE

To investigate the effects of opioid receptor blockade with intranasal naloxone on experimentally induced HAAF.

DESIGN

Randomized, double-blinded, placebo-controlled crossover study.

SETTING

Academic research center.

PARTICIPANTS

Healthy nondiabetic volunteers.

INTERVENTIONS: Paired 2-day studies, 5 to 10 weeks apart, each consisting of 3 consecutive hypoglycemic episodes (hyperinsulinemic hypoglycemic clamps, glucose nadir: 54 mg/dL): 2 on day 1 with administration of intranasal naloxone vs placebo, followed by the third episode on day 2.

MAIN OUTCOME MEASURES: Differences in counterregulatory hormones responses and hypoglycemia symptoms between first and third hypoglycemic episodes in naloxone vs placebo studies.

RESULTS

Out of 17 participants, 9 developed HAAF, confirming variable interindividual susceptibility. Among participants susceptible to HAAF, naloxone maintained some hormonal and symptomatic responses to hypoglycemia and prevented the associated requirement for increased glucose infusion. Unexpectedly, naloxone reduced plasma epinephrine and GH responses to the first hypoglycemic episode but prevented further reduction with subsequent hypoglycemia.

CONCLUSION

This is the first study to report that intranasal naloxone, a widely used opioid receptor antagonist, may ameliorate some features of HAAF. Further investigation is warranted into mechanisms of variable interindividual susceptibility to HAAF and the effects of intranasal naloxone in people with diabetes at risk for HAAF.

Для цитирования: Aleksic Sandra, Lontchi-Yimagou Eric, Mitchell William, Boyle Caroline, Matias Priyanka, Manavalan Anjali, Goyal Akankasha, Carey Michelle, Gabriely Ilan, Hawkins Meredith. Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals.. The Journal of clinical endocrinology and metabolism. 2025. DOI: 10.1210/clinem/dgae479.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.